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Abstract
Summary Healthcare utilization data may be used to
examine the quality of osteoporosis management by identi-
fying dual-energy X-ray absorptiometry (DXA) testing
(sensitivity=98%, specificity=93%) and osteoporosis phar-
macotherapy (κ=0.81) with minimal measurement error.
Introduction In osteoporosis, key quality indicators among
older women include risk assessment by DXA and/or
pharmacotherapy within 6 months following fracture.
Methods The purpose of this study was to examine health-
care utilization data for use as quality indicators of
osteoporosis management. We linked data from 858
community-dwelling women aged over 65 years who
completed a standardized telephone interview about osteo-
porosis management to their healthcare utilization (medical
and pharmacy claims) data. Agreement between self-report
of osteoporosis pharmacotherapy and pharmacy claims was
examined using kappa statistics. We examined the sensitiv-
ity and specificity of medical claims to identify DXA
testing as well as the sensitivity and specificity of medical
and pharmacy claims to identify those with DXA-
documented osteoporosis (T-score≤−2.5).
Results Participants were aged 75 (SD=6)years on aver-
age; 96% were Caucasian. Agreement between self-report
and claims-based osteoporosis pharmacotherapy was very
good (κ=0.81; 95% CI=0.76, 0.86). The sensitivity of
medical claims to identify DXA testing was 98% (95% CI=
95.9, 99.1), with estimated specificity of 93% (95% CI=
89.8, 95.4). We abstracted DXA results from test reports of
359 women, of whom 114 (32%) were identified with
osteoporosis. Medical (osteoporosis diagnosis) and phar-
macy (osteoporosis pharmacotherapy) claims within a year
after DXA testing had a sensitivity of 80% (95% CI=71.3,
86.8) and specificity of 72% (95% CI=66.2, 77.8) to
identify DXA-documented osteoporosis.
Conclusion Healthcare utilization data may be used to
examine the quality of osteoporosis management by
identifying DXA testing and osteoporosis pharmacotherapy
(care processes) with minimal measurement error. However,
medical and pharmacy claims alone do not provide a good
means for identifying women with underlying osteoporosis.
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Health indicators are used as a basis to evaluate the quality
of health care. In osteoporosis, quality indicators among
women aged 65 or more years include risk assessment by
dual-energy X-ray absorptiometry (DXA) and/or pharma-
cotherapy within 6 months following fragility fracture.
Since 2004, the National Center for Quality Assurance in
the USA has included DXA testing and/or treatment within
6 months of fracture as a measure of the quality of
osteoporosis management [1, 2]. In 2007, the province of
Ontario, Canada began funding osteoporosis coordinators
in fracture clinics to help improve osteoporosis pharmaco-
therapy post-fragility fracture—a program modeled after a
successful single-site project [3, 4]. Better understanding of
the accuracy of healthcare utilization (medical and pharma-
cy claims) data to identify DXA testing, osteoporosis
diagnosis, and osteoporosis pharmacotherapy will clarify
the benefits of using these data to track the quality of
osteoporosis management. In Ontario, pharmacy claims are
only available for residents aged 65 or more years.
Exposure to osteoporosis pharmacotherapy before age 65
is not available, and thus, relying on pharmacy claims may
underestimate prior treatment exposure. In addition, to our
knowledge, the validity of claims data to identify DXA
testing has not previously been examined.
To get a better understanding of the accuracy of
healthcare utilization data in Ontario, we linked data from
community-dwelling women aged over 65 years who
completed a standardized telephone interview regarding
osteoporosis management, and their DXA test results when
available, to their healthcare utilization records. We
hypothesized that agreement between self-report of drug
use and pharmacy claims would be good, little measure-
ment error would be found when using medical claims data
to identify DXA testing, and thus collectively, results would
support the validity of healthcare utilization data to examine
quality indicators of osteoporosis management.
Methods
Subjects
Between May 2003 and May 2004, we collected detailed
information regarding osteoporosis management and frac-
ture risk from 871 community-dwelling women aged 65 to
90 years who resided within two regions of Ontario,
Canada [5–9]. The study sample was randomly selected
from a list of 14,163 participants who completed a short
baseline questionnaire between 1995 and 1997 [6]. We
recruited participants by standardized telephone interview
(participation rate=84%, response rate=72%). Respondents
were similar to non-respondents in terms of fracture history,
osteoporosis diagnosis, and osteoporosis treatment [9], as
determined by self-reported data collected at baseline [10].
Data sources and measures
Study questionnaire (self-report of drug use and DXA
testing)
As part of the standardized telephone interview completed
in 2003/2004, we asked participants if they had ever had a
bone density test and recorded information regarding
osteoporosis pharmacotherapy (bisphosphonates, calcito-
nin, and raloxifene) and the use of other agents that may
impact bone density (estrogen therapy, glucocorticoids, and
thyroid medication) as current, past, or never. Question
wording is included in the “Appendix.”
DXA confirmation and DXA—documented osteoporosis
DXA results were sought from participants who reported
having had a DXA test and who completed a signed
release of information form. For these patients, physi-
cians were contacted to confirm that a DXA was
completed and to obtain a copy of the most recent
DXA report. We previously reported that the positive
predictive value for self-report of having had a DXA was
93% when using physician responses as the gold
standard [5]. Among those with a DXA report, we
categorized bone mineral density according to the lowest
T-score at the lumbar spine (L1-4 or L2-4) or hip (femoral
neck or total hip) as normal (T-score≥−1), osteopenic (−1<T-
score>−2.5), or osteoporotic (T-score≤−2.5) [11].
Healthcare utilization data—medical claims
In Canada, physician and hospital services are funded
through publicly financed comprehensive universal health
insurance. In Ontario, claims for physician services are
documented in the Ontario Health Insurance Plan (OHIP)
Claims History Database. Information about inpatient
services are captured in the Canadian Institutes of Health
Information Discharge Abstract Database, and information
about emergency department services are documented in
the National Ambulatory Care Reporting System. Prior to
April 1, 2002, hospital and emergency department records
were coded using the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM). Since then, they have been coded using ICD-10-
Canada (CA). July 1991 is the earliest date for which
individual level data are available.
DXA tests were identified using OHIP claim codes:
J654, J655, J656, J688, J854, J855, J856, J888, X145,
1336 Osteoporos Int (2011) 22:1335–1342X146, X149, X152, X153, X155, and X157. These include
codes for dual-photon absorptiometry, which predates DXA
technology and was used prior to April 1998 [12]. We
considered claims back to July 1991 when individual level
claims data were first recorded in Ontario.
Osteoporosis diagnosis was identified by any OHIP
diagnosis code of 733 or any hospitalization or emergency
department visit code of ICD-9-CM=733.0 or ICD-10-CA=
M80, M81, or M82. We considered diagnosis within 1 year
pre- and post-DXA, as well as within 1 to 5 years before
questionnaire completion.
Healthcare utilization data—pharmacy claims
Residents of Ontario qualify for provincial drug coverage on
the first day of the month following their 65th birthday [13].
Ontario Drug Benefits claims data were used to identify use
of bisphosphonates (alendronate, etidronate, and risedro-
nate), calcitonin, estrogen therapy, raloxifene, oral steroids,
and thyroid medication using a 1-year lookback period from
date of questionnaire completion. “Current users” were those
whose questionnaire completion date fell within a period of
drug treatment—defined by the prescription dispensing date,
number of days of medication supplied, and a 50% grace
period to allow for a missed or reduced dose. “Past use” was
identified by dispensing within the lookback period, without
theoretical overlap with questionnaire date. “Never use” was
coded when there were no relevant pharmacy claims within
the lookback period.
In a sensitivity analysis, we considered a lookback period
of 180 days as this time frame was examined previously [14].
We also considered a lookback period of 5 years restricted to
the subgroup aged 70 or more years to permit a longer period
of time to define “never” use based on pharmacy claims.
Non-osteoporosis formulations (daily or IVetidronate, 40 mg
alendronate, 30 mg risedronate, and 50/100 IU nasal
calcitonin or injection calcitonin) were documented sepa-
rately. We did not consider teriparatide or zoledronic acid
because these were not available during the study period.
Data linkage and eligibility
Study participants were linked to provincial healthcare
utilization databases using probabilistic matching based on
name, date of birth, and residential postal code [15]. While
deterministic linkage using a common unique identifier,
such as health insurance number, would have been
preferable, we did not collect this detail from participants
during the survey. Participants successfully linked to claims
data were eligible for the current study. We then restricted
inclusion to those aged 66 or more years at the time of
questionnaire completion to ensure a minimum of 1 year of
pharmacy claims data prior to questionnaire completion.
All analyses were performed at the Institute for Clinical
Evaluative Sciences.
This study was approved by the Research Ethics Board
of Sunnybrook Health Sciences Centre.
Statistical analysis
Descriptive statistics were used to summarize sociodemo-
graphic characteristics of participants and drug use within
the year prior to questionnaire completion. Agreement
between self-report of drug use and pharmacy claims was
examined using kappa statistics for current versus past/
never use and ever versus never use. Quadratic weighted
kappa statistics were calculated for ordinal values of never,
past, or current use. Kappa statistic values below 0.61
indicate from no to fair agreement, between 0.61 and 0.80
indicate good agreement, between 0.81 and 0.92 indicate
very good agreement, and between 0.93 and 1.00 indicate
excellent agreement [16].
The validityofmedicalclaimsdatatoidentifyDXAtesting
was examined by calculating sensitivity and specificity with
corresponding 95% exact binomial confidence intervals.
Sensitivity was calculated as the proportion of physician-
confirmed DXA tests identified in medical claims data. We
estimated the specificity of DXA testing as the proportion of
participants reporting not to have had a DXA test that were
“correctly” classified as such in medical claims data. Given
that DXA testing among women aged 65 or more years is
considered a quality indicator of osteoporosis management,
we defined a minimum sensitivity and specificity of 90% to
be appropriate.
Sensitivity and specificity of claims data to identify
DXA-documented osteoporosis was determined among the
subgroup with DXA results. Osteoporosis (T-score≤−2.5)
on the DXA report was used as the gold standard diagnosis.
Results
Characteristics of study participants
Eight hundred and sixty-seven of 871 questionnaires
(99.5%) were successfully linked to healthcare utilization
data, and 858 of these subjects (99.0%) were eligible—aged
66 or more years (mean age=75 years, SD=6.0, median=
75, range 66 to 90). The sample included primarily
Caucasian (96%), native English-speaking (82%), non-
smokers (91%), with at least some high school education
(78%; Table 1). About half of the subjects resided in the
Metropolitan area of Toronto (population density of 5,418/
km
2), one third in small towns or rural areas (population
density of 33/km
2), and the remaining 20% in a small city
(population density of 1,086/km
2).
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Agreement between self-report and claims-based osteopo-
rosis pharmacotherapy categorized as current, past, or never
was very good (quadratic weighted κ=0.81, 95% CI=0.76,
0.86). The breakdown by agent is summarized in Table 2.
We found no claims for non-osteoporosis formulations of
bisphosphonates (200 mg or 400 mg daily, or intravenous
etidronate, and 40 mg alendronate or 30 mg risedronate)
or calcitonin (50 or 100 IU nasal or intravenous) within
the year preceding questionnaire completion. One fifth (n
=187) had an eligible oral bisphosphonate, and fewer than
ten participants had prescription claims for nasal calcito-
nin or raloxifene. Agreement between self-report and
pharmacy claims was particularly high for current use of
cyclical etidronate (κ=0.86, 95% CI=0.80, 0.92) and
thyroid medication (κ=0.92, 95% CI=0.88, 0.95). Agree-
ment was particularly poor for ever use of estrogen
therapy (κ=0.33, 95% CI=0.28, 0.39) and oral steroids
(κ=0.35, 95% CI=0.25, 0.46). Results were similar based
on a 180-day lookback period instead of a 365-day
lookback period, or using a 5-year lookback period, and
r e s t r i c t i n gt oa g e s7 0o rm o r ey e a r s( d a t an o ts h o w n ) .
However, applying the 5-year lookback improved the
agreement between ever use of estrogen therapy (from
κ=0.33 to κ=0.45) and oral steroids (from κ=0.35 to
κ=0.47).
Validity of claims data to identify DXA testing
Physicians confirmed the presence of a DXA test in
379 women. The sensitivity of claims data to identify
these 379 confirmed DXA tests was 98% (95% CI=
95.9, 99.1; Table 3). Using self-report of DXA testing as
the gold standard, the estimated specificity of a reim-
bursement claim for DXA testing was 93% (95%CI=
89.8, 95.4).
Validity of claims data to identify DXA-documented
osteoporosis
Of the 379 confirmed DXA tests, we obtained 359
complete DXA reports, and 114 (32%) had DXA-
documented osteoporosis. The sensitivity for identifying
DXA-documented osteoporosis was highest when including
osteoporosis pharmacotherapy claims and/or diagnostic
codes (80% when considering the year after DXA date),
while specificity was highest (over 92%) when we required
both an osteoporosis diagnosis and a pharmacy claim
(Table 4). When we used a definition of any osteoporosis
diagnosis and/or pharmacotherapy within the year follow-
ing DXA testing, sensitivity was 80% (95% CI=71.3,
86.8), and specificity was 72% (95% CI=66.2, 77.8). This
was similar to results using a 365-day lookback in the
pharmacy claims and a 5-year lookback for osteoporosis
diagnoses in medical claims: sensitivity=82% (95% CI=
74.5, 88.7) and specificity=66% (95% CI=59.8, 71.7)—
data not shown in table.
Table 1 Characteristics of study participants, N=858
Characteristic
a N Percent
b
Caucasian 825 96.2
Primary language English 707 82.4
Marital status
Married/common-law 389 45.4
Separated/divorced 51 6.0
Single/widow 416 48.6
Highest level of education
Grade school (through to grade 8) only 187 21.9
High school (through to grade 13) 477 55.9
Post-secondary (at least some college or
university)
189 22.2
Smoking status
Never 514 60.1
Current 78 9.1
Past 263 30.8
Region of residence
c
Metropolitan area 401 46.7
Small city 182 21.2
Town/rural 275 32.1
Clinical risk factors for fracture
Low trauma fracture since age 40 214 24.9
Family history of osteoporosis 240 28.0
Maternal history of hip fracture 53 6.2
Fall in the past year 221 25.8
Early menopause (<45 years) 202 23.5
Body weight, <57 kg 215 25.1
Height loss, >4 cm 146 17.0
Current medication or supplement use
Calcium supplement 425 49.5
Non-estrogen bone-sparing agent
d 173 20.2
Hormone therapy 71 8.3
Oral steroids 19 2.2
Thyroid medication 155 18.1
aData collected as part of a standardized telephone interview and based on
participant self-report
bPercentages adjusted for missing data and may not sum to 100 due to
rounding
cMetropolitan area (21 km
2area with a population density of 5,418/km
2),
small city (34 km
2area with a population density of 1,086/km
2), or town/
rural (2,009 km
2area with a population density of 33/km
2)
dBisphosphonate (alendronate, etidronate, and risedronate), calcitonin,
and /or raloxifene
1338 Osteoporos Int (2011) 22:1335–1342Discussion
Payers of healthcare rely on quality indicators to assess the
performance of their healthcare system, to identify areas for
improvement, and to assess the ability of targeted interven-
tions to improve outcomes. We found healthcare utilization
data to be very good at identifying DXA testing with
sensitivity of 98% and specificity of 93%. We also identified
very good agreement between self-report and claims-based
osteoporosis pharmacotherapy (κ=0.81) despite only having
pharmacy data since age 65 years and applying a 1-year
lookback period. Our data therefore support the use of
healthcare utilization data to measure DXA testing and
osteoporosis pharmacotherapy among women aged over
65 years. Our results are also similar to those reported
among a younger cohort of chronic glucocorticoid users
enrolled in a managed care program with kappa statistics for
agreement between self-report and claims data of 0.80
Description Questionnaire
a ODB data
b Comparison criteria Kappa statistic
c
No. % No. % κ 95% CI
Osteoporosis pharmacotherapy
d
Any bisphosphonate
Current 168 19.6 149 17.4 Dichotomous (current or not) 0.83 0.78, 0.88
Past 36 4.2 38 4.4 Dichotomous (ever or never) 0.80 0.75, 0.85
Never 653 76.2 671 78.2 Ordinal (current, past, never) 0.81 0.77, 0.85
Etidronate
Current 94 11.0 89 10.4 Dichotomous (current or not) 0.86 0.80, 0.92
Past 55 6.4 43 5.0 Dichotomous (ever or never) 0.73 0.67, 0.79
Never 708 82.6 726 84.6 Ordinal (current, past, never) 0.78 0.73, 0.83
Alendronate
Current 39 4.6 34 4.0 Dichotomous (current or not) 0.81 0.72, 0.91
Past 14 1.6 8 0.9 Dichotomous (ever or never) 0.70 0.59, 0.81
Never 804 93.8 816 95.1 Ordinal (current, past, never) 0.75 0.65, 0.85
Risedronate
Current 35 4.1 28 3.3 Dichotomous (current or not) 0.79 0.67, 0.90
Past –
e –
e 9 1.1 Dichotomous (ever or never) 0.79 0.69, 0.89
Never 819 95.6 821 95.7 Ordinal (current, past, never) 0.79 0.69, 0.89
Nasal calcitonin
Current –
e –
e –
e –
e Dichotomous (current or not) 0.40 −0.14, 0.94
Past –
e –
e –
e –
e Dichotomous (ever or never) 0.28 −0.15, 0.72
Never 851 99.3 857 99.9 Ordinal (current, past, never) 0.33 −0.15, 0.82
Raloxifene
Current 7 0.8 –
e –
e Dichotomous (current or not) 0.66 0.35, 0.97
Past –
e –
e –
e –
e Dichotomous (ever or never) 0.58 0.31, 0.86
Never 846 98.7 852 99.3 Ordinal (current, past, never) 0.62 0.34, 0.90
Other medications
Hormone replacement therapy
Current 71 8.3 57 6.6 Dichotomous (current or not) 0.75 0.66, 0.83
Past 265 30.9 47 5.5 Dichotomous (ever or never) 0.33 0.28, 0.39
Never 521 60.8 754 87.9 Ordinal (current, past, never) 0.44 0.38, 0.50
Oral steroids
Current 19 2.2 18 2.1 Dichotomous (current or not) 0.59 0.40, 0.78
Past 82 9.6 18 2.1 Dichotomous (ever or never) 0.35 0.25, 0.46
Never 756 88.2 822 95.8 Ordinal (current, past, never) 0.41 0.30, 0.51
Thyroid medication (e.g., Synthroid® or Eltroxin®)
Current 155 18.1 169 19.7 Dichotomous (current or not) 0.92 0.88, 0.95
Past 30 3.5 –
e –
e Dichotomous (ever or never) 0.86 0.81, 0.90
Never 672 78.4 686 80.0 Ordinal (current, past, never) 0.88 0.85, 0.92
Table 2 Agreement between
self-report and claims-based
drug use history, N=858
aEver in lifetime, see “Appendix”
for question wording
bAny use within 365 days prior
to questionnaire completion;
current use was identified by drug
coverage at the time of question-
naire completion, defined by the
most recent prescription dispens-
ing date prior to the questionnaire
date plus days supplied and 50%
of days supplied grace period
cDichotomous: kappa statistic;
ordinal: quadratic weighted kappa
statistic
dQuadratic weighted kappa
statistic for any osteoporosis
pharmacotherapy (bisphosphonate,
calcitonin, and raloxifene)=0.81,
95% CI=0.76, 0.86
eNumbers suppressed due to small
cell sizes (<5)
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0.79 in our study) for risedronate [14].
Although we identified very good agreement between
self-report and claims data for osteoporosis pharmacother-
apy, we found that the ability of claims data to identify past
use of estrogen or oral steroids was poor, and both
exposures have implications for bone health. These results
are not surprising since estrogen therapy is commonly
prescribed at the time of menopause, and oral steroids may
be prescribed for a number of conditions that are not
specific to those aged over 65 years. Nonetheless, agree-
ment between claims data and self-report of thyroid
medication use that is intended for chronic use was very
good.
Our results also identify the importance of pharmacy
claims data to help identify DXA-documented osteoporosis,
as relying on medical diagnosis claims alone identified only
43% of women with DXA T-score≤−2.5. The combination
of medical diagnosis claims and pharmacy claims proved to
be a good proxy for DXA-documented osteoporosis, with a
sensitivity of 80% and specificity of 72%. Our results
therefore suggest that healthcare utilization data may
provide a reasonable method to identify those most likely
to have DXA-document osteoporosis. Although we had
DXA results for only 359 of the 501 women (72%)
reporting to have had a DXA, the prevalence of osteopo-
rosis is similar to prior age-stratified prevalence in North
American women [17–19]. We thus believe little bias was
introduced by only having data for a subset of women who
reported having been tested by DXA.
We report the ability of healthcare utilization data to
identify DXA-documented osteoporosis but cannot com-
Table 4 Ability of claims data to identify patients with dual-energy X-ray absorptiometry (DXA)-documented osteoporosis among those having
had a DXA test, N=359
Medical and pharmacy claims DXA-documented osteoporosis (T-score≤−2.5)
Yes, N=114 No, N=245
Sensitivity (95% CI) Specificity (95% CI)
Within 365 days before DXA date
Any osteoporosis diagnostic code
a 28.9 (20.8, 38.2) 91.0 (86.7, 94.3)
Any pharmacotherapy for osteoporosis
b 52.6 (43.1, 62.1) 80.8 (75.3, 85.6)
Any osteoporosis diagnostic code and/or pharmacotherapy 61.4 (51.8, 70.4) 78.4 (72.7, 83.4)
Any osteoporosis diagnostic code and pharmacotherapy 20.2 (13.2, 28.7) 93.5 (89.6, 96.2)
Within 365 days after DXA date
Any osteoporosis diagnostic code
a 43.0 (33.7, 52.6) 85.3 (80.2, 89.5)
Any pharmacotherapy for osteoporosis
b 71.1 (61.8, 79.2) 79.2 (73.6, 84.1)
Any osteoporosis diagnostic code and/or pharmacotherapy 79.8 (71.3, 86.8) 72.2 (66.2, 77.8)
Any osteoporosis diagnostic code and pharmacotherapy 34.2 (25.6, 43.7) 92.2 (88.2, 95.3)
DXA dual-energy X-ray absorptiometry
aAlmost every claims-based diagnosis of osteoporosis was identified using OHIP claim codes. Only one case was identified using ICD codes alone;
however, this case was also identified by osteoporosis pharmacotherapy
bOsteoporosis formulations of bisphosphonates (alendronate, etidronate, and risedronate), nasal calcitonin, and /or raloxifene
Table 3 Proportion of women with a dual-energy X-ray absorptiometry (DXA) test identified in claims data among those reporting to have had a
DXA test, by length of claims lookback period, N=501
Percent with DXA identified using medical services claims data,
a lookback period
1 year 2 years 3 years 5 years From 1991
c
DXA confirmed by physician, n=379 35.9 60.7 75.2 90.0 97.9
DXA not confirmed by physician, n=27 0.0 7.4 11.1 18.5 29.6
Missing,
b n=95 25.3 47.4 64.2 74.7 87.4
Five hundred one of 858 participants reported having ever had DXA test during the standardized telephone interview
aOHIP fee code, any of J654, J655, J656, J688, J854, J855, J856, J888, X145, X146, X149, X152, X153, X155, and X157
bPatient self-report yes, but either did not receive written permission to obtain the result or did not receive a physician response to our request for
information regarding DXA testing
cJuly 1991 is when individual data were first available, i.e., as far back as healthcare utilization data capture
1340 Osteoporos Int (2011) 22:1335–1342ment on the ability of these data to identify asymptomatic,
untreated osteoporosis. Nonetheless, among a subgroup
having been tested by DXA, healthcare utilization data
may provide a reasonable method to identify those most
likely to have DXA-documented osteoporosis. A recent
study from Manitoba, Canada similarly found that including
osteoporosis pharmacotherapy as well as osteoporosis diag-
nosis improved the ability of healthcare utilization data to
identify DXA-documented osteoporosis. This study included
all patients aged 50 or more years who had DXA and
recommends the use of age, fracture diagnoses, and persis-
tence with osteoporosis pharmacotherapy to improve the
identification of patients with DXA-documented osteoporosis
[20]. However, the ability of these more comprehensive
algorithms to identify DXA-documented osteoporosis had
similar discriminatory performance to that using osteoporosis
diagnosis or pharmacotherapy in our study, given our
underlying prevalence of osteoporosis of 32%. Our results
therefore suggest that among women aged over 65 years,
identification of DXA-documented osteoporosis based on
medical diagnosis codes and osteoporosis pharmacotherapy
may be as robust as more complex algorithms that also
consider fracture history and age.
In addition to those already mentioned, several other study
limitations are worth noting. First, we studied women in a
single province of Canada that uses provincial-specific claim
codes for outpatient physician services (OHIP claims).
However, given that the OHIP diagnostic code for osteopo-
rosis (733) is essentially the same as the ICD-9-CM code of
733.0, we believe that our results will generalize to other
jurisdictions that use ICD-9-CM codes in the outpatient
setting. Similarly, although we used provincial-specific
procedural codes to identify DXA testing, our results are
expected to generalize to other jurisdictions that operate
on a fee-for-service basis. Second, our results are most
applicable to use of bisphosphonates, as we had few
exposures to nasal calcitonin or raloxifene and no
exposure to teriparatide or zoledronic acid. Finally, by
using only the most recent DXA test to define DXA-
document osteoporosis, we may have misclassified some
patients whose BMD improved with therapy yet had
been classified as osteoporotic on a prior DXA.
Despite limitations, our study has many strengths. We
studied a broad sample of older women residing within
different regions of Ontario, and the prevalence of osteopo-
rosis inour studyisconsistentwithage-stratifiedestimatesfor
North American women [17–19]. We therefore believe that
our study results are highly representative of the ability of
claims data to identify quality indicators of osteoporosis
management among older women in Ontario, and that our
results may generalize to other jurisdictions that use health-
care administrative claims for billing purposes. In conclu-
sion, healthcare utilization data may be useful as quality
indicators of the assessment of DXA testing and osteoporo-
sis pharmacotherapy (care processes), with minimal mea-
surement error in women over 65 years of age. However,
medical and pharmacy claims do not provide a good means
for identifying women with underlying osteoporosis.
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Appendix
Self-report of drug use—standardized telephone
questionnaire wording
1
Have you ever been treated by a doctor with the following:
Hormone replacement therapy (estrogen by mouth or
patch)
Evista® (raloxifene)
Prednisone (cortisone/steroids)
2
Thyroid pills such as Synthroid® or Eltroxin®
Have you ever been treated by a doctor with medication
for bone health, such as Actonel®, Calcimar®, Didronel®
or Didrocal®, Fluotic®, Fosamax®, Miacalcin® or other
medication?
Actonel® (risedronate)
Didronel®, Didrocal® (etidronate)
Fosamax® (alendronate)
Calcimar®, Miacalcin®, nasal spray (calcitonin)
Other, specify:
1 Response options: never, now, and past.
2 Collected responses for inhaled, injections, and oral separately.
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